<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied telomerase regulation and telomere length in hematopoietic progenitor cells from peripheral blood and bone marrow from patients with <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0005558'>chronic leukemia</z:hpo> and <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>CD34+ cells from a total of 93 patients with either <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n = 25), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>; n = 21), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL; n = 18), <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>; n = 16), or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; n = 13) were analyzed before and in 19 patients after ex vivo expansion in the presence of multiple cytokines (kit ligand, interleukin-3, interleukin-6, and granulocyte colony-stimulating factor plus erythropoietin) </plain></SENT>
<SENT sid="2" pm="."><plain>Compared with hematopoietic progenitor cells from <z:mpath ids='MPATH_458'>normal</z:mpath> donors (n = 108), telomerase activity (TA) was increased 2- to 5-fold in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase (CP)-<z:mp ids='MP_0005481'>CML</z:mp>, CLL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, accelerated phase (AP) and <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> (BP)-<z:mp ids='MP_0005481'>CML</z:mp>, basal TA was 10- to 50-fold higher than <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>TA of CP-<z:mp ids='MP_0005481'>CML</z:mp> CD34+ cells was up-regulated within 72 h of ex vivo culture, peaked after 1 week, and decreased below detection after 2 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, TA in AP/BP-<z:mp ids='MP_0005481'>CML</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> CD34+ cells was down-regulated after 1 week of culture and decreased further thereafter </plain></SENT>
<SENT sid="6" pm="."><plain>The expansion potential of CD34+ cells from patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> was considerably decreased compared with CD34+ cells from <z:mpath ids='MPATH_458'>normal</z:mpath> donors </plain></SENT>
<SENT sid="7" pm="."><plain>The average expansion of cells from leukemic individuals was 6.5-, 2.3-, 0.6-, and 0.2-fold in weeks 1, 2, 3, and 4, respectively, whereas expansion of <z:mpath ids='MPATH_458'>normal</z:mpath> cells was 5- to 15-fold higher </plain></SENT>
<SENT sid="8" pm="."><plain>In serial expansion culture, a median telomeric loss of 0.7 kbp was observed during 3-4 weeks of expansion </plain></SENT>
<SENT sid="9" pm="."><plain>Our results demonstrate that up-regulation of telomerase is similar in CD34+ cells from CP-<z:mp ids='MP_0005481'>CML</z:mp>, CLL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and in <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoietic cells during the first week of culture, whereas in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and AP/BP-<z:mp ids='MP_0005481'>CML</z:mp>, telomerase is high at baseline and down-regulated during expansion culture </plain></SENT>
<SENT sid="10" pm="."><plain>High levels of telomerase in leukemic progenitors at baseline may be a feature of both the malignant phenotype and rapid cycling </plain></SENT>
<SENT sid="11" pm="."><plain>Telomerase down-regulation during culture of leukemic cells may be due to the decreased expansion potential or repression of <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis, or in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> it may be due to the partial differentiation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells, shown previously to be associated with loss of TA </plain></SENT>
<SENT sid="12" pm="."><plain>Telomere shortening during ex vivo expansion correlated with low levels of TA, particularly in <z:hpo ids='HP_0011010'>chronic</z:hpo> leukemic and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progenitors where telomerase was insufficient to protect against telomere bp loss during intense proliferation </plain></SENT>
</text></document>